SAB Biotherapeutics Financial Overview
SAB Biotherapeutics's market cap is currently $189.95M. The company's EPS TTM is $-0.21; its P/E ratio is -1.24; SAB Biotherapeutics is scheduled to report earnings on November 13, 2025, and the estimated EPS forecast is $-0.20. See an overview of income statement, balance sheet, and cash flow financials.
